Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Demand may continue to increase as more GLP-1 agonists are approved for other conditions, such as preventing heart attacks or strokes in adults with cardiovascular disease
** This endpoint was not included in the hierarchy testing and is only for informative purposes
Other GLP-1R/GIPR co-agonists such as Cpd86 (Eli Lilly), ZP-DI-70 (Zealand) and NN9709/MAR709 (Novo Nordisk/Marcadia) have also been designed and tested in preclinical models of obesity and subsequently advanced to clinical trials (Table 1)
Its been shown to lower HbA1c levels more effectively than semaglutide, providing a potentially brighter outlook for those seeking stringent blood sugar management
Understanding these contraindications is essential for healthcare providers and patients to ensure safe and appropriate use of this compounded medication
